105results about How to "High therapeutic effect" patented technology

Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.

A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.

An M toxin of type A botulinum toxin (HA-negative substance) and a mixture of L toxin and LL toxin (HA-positive substance) are compared and examined in inhibitory action for neuromuscular transmission and therapeutic index. As a result, it is found that M toxin of type A botulinum toxin has characteristics of: 1) having an excellent inhibitory action for neuromuscular transmission; 2)showing a high therapeutic index; 3) showing a low antigenicity and 4) suffering from little reduction in efficacy even after repeatedly administered, compared with the mixture of L toxin and LL toxin. Owing to these characterics, the M toxin of type A botulinum toxin is particularly useful as a therapeutic agent for diseases caused by hypermyotonia such as strabismus, blepharospasm, facial spasms, spasmodic torticollis, paralysis after cerebral apoplexy, infantile cerebral paralysis, spasmodic phonopathy, headache such as migraine, chronic pain such as lumbago, stiff shoulder, muscular relaxation disorder accompanied with onset of Parkinson's disease or multiple sclerosis, myofascial pain syndrome, masticatory spasm, chronic anal fissure, urinary inconsistency, grinding of teeth, facial myokymia, tic, topical dystonia and wrinkles.

Provided is a radiotherapeutic agent, including a composite particle, which is obtained by binding a molecule that specifically recognizes a target to a substrate particle including titanium peroxide, and which generates reactive oxygen through irradiation with a radiation. Further, because the radiotherapeutic agent contains the molecule that specifically recognizes a target, the radiotherapeutic agent has a function of accumulating in the target. The radiotherapeutic agent is capable of enhancing effects of radiotherapy, and is capable of reducing side effects on a living body to efficiently attack the target.

Disclosed herein are compositions and methods for the delivery and targeting of therapeutics using nanometer sized polysaccharide structures. The methods and compositions described herein afford improved efficacy for pharmaceuticals such as anti-tumor drugs on metastatic tumor. The methods described herein are applicable to all chemotherapeutic agents and are especially useful for poorly soluble (hydrophobic) drugs which when formulated with the present compositions render them deliverable in physiological fluids. The methods and compositions described herein also improve the efficacy of pharmaceutical agents by targeting carbohydrate receptors specific to tumors that mediate endocytosis or enhance delivery of the drug to the ultimate site of action.

TECHNICAL FIELD: Lotion for therapy of dermatitis TECHNICAL PROBLEM: To provide a lotion for therapy effective against atopic dermatitis.

MEANS FOR SOLVING: It has a composition: Lightyellow Sophora Root, 3%; Turmeric, 2%; Magnolia Bark, 2%; Moutan Bark, 2%; Isatis Leaf, 1%; Borneo Camphor Tree (Dryobalanops aromatica Gaertn.f.), 1%; Amur Cork Tree, 2%; Angelicae Dahuricae Root, 1%; Lemon, 3%; Smartweed, 2%; Licorice, 0.5%; Cnidii Rhizoma, 0.5%; Japanese Angelica Root, 0.5%; salicylic acid, 0.5%; resorcinol, 0.5%; alcohol, 30%; and water, 48.5%.

A significant therapeutic effect against atopic dermatitis is obtained by a synergistic effect between antibacterial, antiviral, antiallergic, antiphlogistic, and blood-circulation accelerating actions as pharmacological effects of Lightyellow Sophora Root, Turmeric, Magnolia Bark, Moutan Bark, Isatis Leaf, Borneo Camphor Tree (Dryobalanops aromatica Gaertn.f.), Amur Cork Tree, Angelicae Dahurikae Root, Lemon, Smartweed, and Licorice, accelerating action for skin permeation and antifungal-sterilizing action of Cnidii Rhizoma and Japanese Angelicae Root, accelerating action for keratinization and antifungal-sterilizing action of salicylic acid and resorcinol, as described above. Principal Use: It is used for the therapy of dermatitis, particularly of atopic dermatitis.

Disclosed is an agent for prevention or treatment of iron overload disorders, comprising 22β-methoxyolean-12-ene-3β,24(4β)-diol or a pharmacologically acceptable salt thereof.

An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.

Disclosed is a recombinant human adenovirus type 5 adenovirus construct, in which a 920-946 nt sequence of ADV5 genome and a 28532-29360 nt sequence of the E3 region are deleted while a foreign cDNA fragment is reversely inserted into the deleted E3 region. A method for preparing the recombinant ADV5 construct is also provided. The construct provided herein presents a tumor-specific replication, tumor-specific expression of the inserted anti-gene and tumor-specific bystander effects, and is suitable for use in tumor therapy.

A cancer therapeutic agent according to an embodiment of the present invention contains, as active ingredients, IL-18 and one or more antibodies selected from the group consisting of an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-PD-L2 antibody, an anti-CTLA-4 antibody, an anti-CD25 antibody, an anti-CD33 antibody, and an anti-CD52 antibody.

The invention provides an M1 type MAP (macrophage activation peptide) and IL-2 (interleukin-2) fusion protein and fusion gene as well as an expression vector and a construction method of the expression vector. The amino acid sequence of the fusion protein is shown as SEQ ID NO:1. A multi-expression M1 type MAP and an IL-2 gene are adopted for splicing coexpression and constitute key factors for activating immune response. The fusion protein can perform a function and play a role simultaneously in intestinal mucosa and mesenteric lymph nodes and has remarkable treatment and regulation functions on PRRSV and PCV2, the quantity of M2 type macrophages is reduced by stimulating proliferation and activation of M1 type macrophages, and immunosuppression is recovered effectively.

A marker can determine whether or not a patient has a therapeutic response to an anti-cancer agent. A novel cancer therapy employs the marker. The marker can be N-acetylglucosamine, an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, lauric acid, 6-phosphogluconic acid, butyric acid, 4-methylpyrazole, isobutylamine, glycolic acid, NADH, NAD⁺, or a substance involved in the metabolism of any of these substances.

In order to obtain high therapeutic effects in treating malignant tumors, particularly melanoma, a new therapeutic method having less side effects, or a new therapeutic method which can provide further high therapeutic effects at conventional doses of agents has been desired. An object of the present invention is to provide a medicament which can provide higher therapeutic effects than any one of a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof alone, and a substance which activates an immunocomponent cell and a substance having an antitumor activity alone, by combining a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof with at least one of a substance which activates an immunocomponent cell and a substance having an antitumor activity. Also, the medicament is expected to relieve side effects which were problems in the case of administration of individual single agents.

A pharmaceutical composition for therapy of coronary artery narrowing or blockage, which comprises a sustained release preparation containing an angiogenesis factor or a gene encoding the same and a gelatin hydrogel is disclosed. Examples of the angiogenesis factor which may be used include e.g., bFGF and other FGFs, VEGF, HGF, PDGF, TGF, angiopoietin, HIF, cytokine, chemokine, adrenomeduline and the like.

Provided are: a novel compound having a structure different from that of existing drugs; a novel microorganism capable of producing the novel compound; and further; a novel compound effective to a multiple-drug-resistant bacterium. To provide a novel compound having a high therapeutic effect which can be expected to have a low hurdle for practical realization by selecting an intended compound from many candidate compounds based not only on an antibacterial activity but also on evaluation including a therapeutic effect, a cyclic peptide compound shown by the following formula (1) or a pharmaceutically allowable salt thereof and a microorganism with Accession No. NITE BP-870 or a microorganism mutated naturally or artificially therefrom are provided.

(In the formula (1), R¹ represents an acyl group having 7, 8, or 9 carbon atoms and optionally containing a substituent group; R² represents a methyl group or a hydrogen atom; and R³ represents an ethyl group or a methyl group.)

An antibacterial agent comprising a compound represented by the following general formula (I), which can exhibit potent antibacterial activity against bacteria that have acquired resistance to quinolones (in the formula, R¹ and R⁴ represents hydrogen atom, hydroxyl group, or a lower alkoxy group; R² and R³ represents hydrogen atom or hydroxyl group; W represents hydrogen atom, a lower cyclic alkyl group, or a lower alkoxy group; R^1′ and R^5′ represents hydrogen atom; R^2′ and R^3′ represents hydrogen atom, hydroxyl group, or a lower alkoxy group; and R^4′ represents hydrogen atom or hydroxyl group).